Key Financial Metrics:

1. Total Business Revenue: $2.7 billion for the quarter, an increase of 24% compared to the prior year.
2. North America Business: Grew approximately 5% to more than $1.2 billion. Excluding the impact of EpiPen, the business would have been up approximately 20%.
3. European Sales: Totaled about $900 million, a year-over-year increase of 53%.
4. Rest of the World Sales: Totaled about $580 million, a year-over-year increase of 34%.
5. Operating Platform: Decrease in SG&A spend on a percentage basis year over year, indicating progress in realizing synergy targets.
6. Quality Assurance: Working closely with FDA to resolve any issues and received a GMP compliance certificate from other regulatory entities.

These key financial metrics highlight the strong performance and growth of the company's regional segments, as well as the progress in operational efficiency and quality assurance efforts.